coadministered cagrilintide and semaglutide in adults with overweight or obesity Semaglutide, Obesity. June 22,, 2025. DOI: 10.1056/NEJMoa2502081, Cagrilintide–Semaglutide in Adults with, Overweight or and Type 2 Cagrilintide & Semaglutide in Overweight

Clinical outcomes are the same as brand-name products, with patients typically losing 15-22% of body weight over 6-12 months

2025] Faculty of Sexual and Reproductive Healthcare (FSRH)

And at three to five years, people still have 20% off

The company is exploring alternative methods of administering GLP-1 medications beyond injectables, with the goal of achieving scalable production to reach a wider population, said Karla Alcazar, President and General Manager, Lilly Latin America, during Mexico Health Summit 2025.

Timing Considerations Administering peptides on an empty stomach produces stronger GH release

Drug Interactions Some drugs (e.g., diuretics, corticosteroids, antihypertensives, carbonic anhydrase inhibitors) can affect metformin's safety and effectiveness